23738-81-0Relevant articles and documents
Histone Deacetylase 2 (HDAC2) Inhibitors Containing Boron
Kavianpour, Poya,Gemmell, Madeleine C. M.,Kahlert, Jan U.,Rendina, Louis M.
, p. 2786 - 2791 (2020/06/25)
Histone deacetylase enzymes (HDACs) are responsible for the global silencing of tumour-suppressor genes. Treatment with a histone deacetylase inhibitor (HDACi) can reverse this process and restore normal cell function. Herein, we report a small series of boron-based (boronic acid, boronate ester and closo-1,2-carborane) HDAC2 inhibitors with IC50 values in the nanomolar range. The boronate ester 4 b was the most potent compound assessed in this study (IC50=40.6±1.5 nM), followed closely by the 1,2-closo-carborane (IC50=42.9±1.5 nM). Compound 4 b exceeds the potency of the related gold-standard HDAC pan-inhibitor vorinostat (1) toward this particular HDAC isoform.
Tumour-targetted Boranes. Part 3. Synthesis of Carbamate-linked Nitroimidazolyl Carboranes Designed for Boron Neutron Capture Therapy of Cancer
Scobie, Martin,Threadgill, Michael D.
, p. 2059 - 2064 (2007/10/02)
Carboranes targetted to specific tumour tissues are important for boron neutron capture therapy of cancer (BNCT).Carbamoylation of 2-ethoxy>ethanol 5 and 1-(chloromethyl-2-(nitroimidazol-1-yl)ethanol 6 with carboran-1-yl isocyanate (generated in situ by a Curtius rearrangement of carborane-1-carbonyl azide) gave the corresponding carbamate-linked nitroimidazolylcarboranes 16 and 17.A similar reaction of 4-carboranylphenyl isocyanate with 6 afforded the corresponding carbamate 24.